Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection.
about
Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human populationInfluenza virus hemagglutinin stalk-based antibodies and vaccinesShort-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptideH5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer modelAvian influenza A H5N1 virus: a continuous threat to humans.Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine developmentProspects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants.Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virusGlobular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in miceIdentification of a highly conserved H1 subtype-specific epitope with diagnostic potential in the hemagglutinin protein of influenza A virus.Novel vaccines against influenza viruses.Passive immune neutralization strategies for prevention and control of influenza A infections.Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses.A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virusVirus-like particles as universal influenza vaccinesImmunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNA-liposome complex induced protection against lethal influenza virus infection in mice.Cross-protective immune responses elicited by live attenuated influenza vaccinesEmerging antiviral strategies to interfere with influenza virus entry.Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin.The epitope and neutralization mechanism of AVFluIgG01, a broad-reactive human monoclonal antibody against H5N1 influenza virus.Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing proteinAnimal Models for Influenza Virus Pathogenesis and Transmission.Properties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza virusesWide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies.Cell penetrable human scFv specific to middle domain of matrix protein-1 protects mice from lethal influenza.A high-affinity CDR-grafted antibody against influenza A H5N1 viruses recognizes a conserved epitope of H5 hemagglutinin.Immunogenicity of low-pH treated whole viral influenza vaccine.Monoclonal antibody specific to HA2 glycopeptide protects mice from H3N2 influenza virus infectionOral Delivery of a Novel Attenuated Salmonella Vaccine Expressing Influenza A Virus Proteins Protects Mice against H5N1 and H1N1 Viral InfectionInactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases.Unraveling of a neutralization mechanism by two human antibodies against conserved epitopes in the globular head of H5 hemagglutinin.Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines.Cross-reactive human B cell and T cell epitopes between influenza A and B viruses.Epitope specificity of anti-HA2 antibodies induced in humans during influenza infectionA novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2.Protein engineering strategies for the development of viral vaccines and immunotherapeutics.Mechanism of neutralization of herpes simplex virus by antibodies directed at the fusion domain of glycoprotein B.
P2860
Q24655857-5D0E160E-B636-463B-9062-FE6EB634420CQ27001190-F69F05C9-4E0D-479E-9FFA-EA76198ADB57Q27666404-AECDDE4B-1F6A-4379-8E4A-EF1865960B22Q28741304-07D6AF3C-DF41-4DE9-A6EF-99C54C08DFEDQ30224462-936E8AA1-D79F-44A2-8E4E-7C924564F507Q30226873-9B6E56EE-9E0D-4904-93BC-6A3D35F61731Q30375714-53914706-4DAF-4FA1-875D-97DD1D1451E5Q30377663-EE3175B4-3E26-4527-9929-00F8AE000421Q30379914-FD19CCF0-1436-492F-AFC6-2CA30054199DQ30387031-DB032F1A-F1D4-4248-90D0-23BDB909FF47Q30391974-3FA9AE23-306E-4DBE-BDD5-215C2B18679EQ30406634-6E2A58A8-3731-48F0-993C-1E4089A0D3C6Q30407716-56F0AAD8-EB19-4BC7-9CD0-B3F803D64CAEQ30413158-8E11AD19-7596-489E-B408-C602FF896B19Q30414515-A55B41A3-5CA9-4197-95BF-52882B6352AAQ30420210-175C7365-3BC2-4665-AFE3-D4F53E0694A4Q30421558-2A880525-7DC6-4C01-8006-4818AA31AFD5Q30423481-02D7E64F-5979-43A9-AC13-9C6D65294565Q30426540-E05DB246-7141-4846-B7DB-91054035DEE6Q30432421-932D16F8-6EC2-4C4E-888C-D835BDD3BEFEQ30535722-F393A986-D63C-4854-9A68-0EE05690EE0FQ34291530-F2A47015-598E-49CD-AF02-8859F3E49154Q34437654-24A3C987-C014-477E-875D-C222AC0083FDQ34714853-D0AE558E-03EA-4D00-BC8E-CD487F886898Q34737817-37B8EDD9-5362-47D3-B601-3D10B8CCE0FCQ34756837-C6A99503-983C-4A3B-BEF9-9421C925C78EQ35014925-D918E9E1-F35B-4634-B385-AB5B1A51DB0EQ35099676-4FF166F0-2212-4F4E-BAE2-1FB924D64D93Q35154124-BACA3042-92E7-4234-A088-B795283CEB46Q35190882-F08AF09D-E28E-4C54-B28B-881FF424D1D7Q35666065-E4C9B687-BB49-40BA-BD4A-DB440F81C0CCQ36227268-2188C71D-B15B-4021-B24D-01DB4FA07B6EQ36596819-54E5660B-4DE5-480F-8D3B-8C565BCBE19EQ36667857-3023A433-9F31-453E-B42C-773D40D34A7BQ36779713-5D124D5F-F39E-4B34-9DBF-9F38E5248311Q37053710-8A156E6E-4B36-47E7-8C20-91952DF307E4Q37087170-C914E662-4261-46A4-B0AF-56B876E253CBQ37547653-A6291DCD-634B-42EE-8989-B1D199503C3BQ37625877-D654429E-062A-410C-8933-9729C04C0E23Q37644037-ADCC01D1-E335-4DBF-BC91-A24200CEA001
P2860
Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Monoclonal antibodies against ...... luenza A virus H5N1 infection.
@en
Monoclonal antibodies against ...... luenza A virus H5N1 infection.
@nl
type
label
Monoclonal antibodies against ...... luenza A virus H5N1 infection.
@en
Monoclonal antibodies against ...... luenza A virus H5N1 infection.
@nl
prefLabel
Monoclonal antibodies against ...... luenza A virus H5N1 infection.
@en
Monoclonal antibodies against ...... luenza A virus H5N1 infection.
@nl
P2093
P2860
P356
P1433
P1476
Monoclonal antibodies against ...... fluenza A virus H5N1 infection
@en
P2093
Hui-Ting Ho
Michael Goutama
Mookkan Prabakaran
Sumathy Velumani
P2860
P304
P356
10.1128/JVI.02165-08
P407
P577
2008-12-24T00:00:00Z